1. Home
  2. NBH vs PRQR Comparison

NBH vs PRQR Comparison

Compare NBH & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NBH
  • PRQR
  • Stock Information
  • Founded
  • NBH 2002
  • PRQR 2012
  • Country
  • NBH United States
  • PRQR Netherlands
  • Employees
  • NBH N/A
  • PRQR N/A
  • Industry
  • NBH Finance/Investors Services
  • PRQR Biotechnology: Pharmaceutical Preparations
  • Sector
  • NBH Finance
  • PRQR Health Care
  • Exchange
  • NBH Nasdaq
  • PRQR Nasdaq
  • Market Cap
  • NBH 314.8M
  • PRQR 309.5M
  • IPO Year
  • NBH N/A
  • PRQR 2014
  • Fundamental
  • Price
  • NBH $10.45
  • PRQR $2.57
  • Analyst Decision
  • NBH
  • PRQR Strong Buy
  • Analyst Count
  • NBH 0
  • PRQR 5
  • Target Price
  • NBH N/A
  • PRQR $7.60
  • AVG Volume (30 Days)
  • NBH 85.9K
  • PRQR 566.5K
  • Earning Date
  • NBH 01-01-0001
  • PRQR 11-07-2024
  • Dividend Yield
  • NBH 4.34%
  • PRQR N/A
  • EPS Growth
  • NBH N/A
  • PRQR N/A
  • EPS
  • NBH 0.12
  • PRQR N/A
  • Revenue
  • NBH N/A
  • PRQR $20,506,357.00
  • Revenue This Year
  • NBH N/A
  • PRQR $235.11
  • Revenue Next Year
  • NBH N/A
  • PRQR N/A
  • P/E Ratio
  • NBH $87.04
  • PRQR N/A
  • Revenue Growth
  • NBH N/A
  • PRQR 306.68
  • 52 Week Low
  • NBH $8.75
  • PRQR $1.61
  • 52 Week High
  • NBH $11.01
  • PRQR $4.62
  • Technical
  • Relative Strength Index (RSI)
  • NBH 28.43
  • PRQR 35.24
  • Support Level
  • NBH $10.56
  • PRQR $2.27
  • Resistance Level
  • NBH $10.82
  • PRQR $2.95
  • Average True Range (ATR)
  • NBH 0.09
  • PRQR 0.30
  • MACD
  • NBH -0.03
  • PRQR -0.12
  • Stochastic Oscillator
  • NBH 1.61
  • PRQR 17.89

About NBH Neuberger Berman Municipal Fund Inc.

Neuberger Berman Intermediate Muni Fund is a closed-end management investment company that invests mainly in municipal securities. It aims to provide common stockholders a high level of current income exempt from Federal income tax.

About PRQR ProQR Therapeutics N.V.

ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.

Share on Social Networks: